The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database
Open accessAbstract
Purpose: Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years. Methods: We used the Surveillance, Epidemiologic, and End Results (SEER) database to determine the incidence of SCLC over the last 30 years. In addition, we sought to determine sex- and stage-based differences in the incidence and survival of SCLC among a proportion of reported cases of lung cancer over the last 30 years (1973 to 2002). Joinpoint analyses were applied to test the trends in annual percentage change for statistical significance. Results: The proportion of SCLC (among all lung cancer histologic types) decreased from 17.26% in 1986 to 12.95% in 2002. Of all patients with SCLC, the proportion of women with SCLC increased from 28% in 1973% to 50% in 2002. A modest but statistically significant improvement in 2- and 5-year survival was noted among both limited-stage SCLC and extensive-stage SCLC cohorts during the study period. Conclusion: Our analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years. Possible explanations for the decreasing incidence include the decrease in the percentage of smokers and the change to low-tar filter cigarettes. Despite trends toward modest improvement in survival, the outcome remains very poor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberg, A. J., & Samet, J. M. (2010) · Murray and Nadel's Textbook of Respiratory Medicine · doi:10.1016/b978-1-4160-4710-0.00046-8 · Cited by 1,060
Alberg, A. J., Brock, M. V., & Samet, J. M. (2016) · Murray and Nadel's Textbook of Respiratory Medicine · doi:10.1016/b978-1-4557-3383-5.00052-x · Cited by 781
The Less Harmful Cigarette: A Controversial Issue. A Tribute to Ernst L. Wynder
Hoffmann, D., Hoffmann, I., & El-Bayoumy, K. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000260u · Cited by 745
Wingo, P. A., Ries, L. A. G., Giovino, G. A., Miller, D. S., Rosenberg, H. M., Shopland, D. R., Thun, M. J., & Edwards, B. K. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.8.675 · Cited by 582
Travis, W. D., Travis, L. B., & Devesa, S. S. (1995) · Cancer · doi:10.1002/1097-0142(19950101)75:1+<191::aid-cncr2820751307>3.0.co;2-y · Cited by 582
Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis
Khuder, S. A. (2001) · Lung Cancer · doi:10.1016/s0169-5002(00)00181-1 · Cited by 522
Hoffmann, D., Djordjevic, M. V., & Hoffmann, I. (1997) · Preventive Medicine · doi:10.1006/pmed.1997.0183 · Cited by 421
Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1563 · Cited by 381
Hoffmann, D., Brunnemann, K. D., Prokopczyk, B., & Djordjevic, M. V. (1994) · Journal of Toxicology and Environmental Health · doi:10.1080/15287399409531825 · Cited by 330
The changing epidemiology of lung cancer in Europe
Janssen-Heijnen, M. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00230-7 · Cited by 301
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., Postmus, P., Collette, L., Musat, E., & Senan, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071780 · Cited by 1,133
Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,083
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review
Arbour, K. C., & Riely, G. J. (2019) · JAMA · doi:10.1001/jama.2019.11058 · Cited by 1,060
Lung cancer: Biology and treatment options
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y.-W., & Buchanan, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,014
Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
Hou, J.-M., Krebs, M. G., Lancashire, L., Sloane, R., Backen, A., Swain, R. K., Priest, L. J. C., Greystoke, A., Zhou, C., Morris, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3716 · Cited by 842
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
Youlden, D. R., Cramb, S. M., & Baade, P. D. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818020eb · Cited by 812
Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., Cheema, P. K., Rodriguez-Abreu, D., Wollner, M., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00793 · Cited by 760
“Small-cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy strongly associated with tobacco use that accounts for approximately 15% of all lung cancers.(1) SCLC is characterized by a rapid doubling time and high growth fraction, and approximately two thirds of patients present with metastases at diagnosi…”
BackgroundNothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
Self-citationMishima, S., Nozaki, Y., Mikami, S., Kihira, E., Iikura, M., Koketsu, R., Sugiyama, H., Masuda, T., Kaname, H., Egami, Y., et al. (2015) · Case Reports in Gastroenterology · doi:10.1159/000381140 · Cited by 631
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Dingemans, A.-M. C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.207 · Cited by 626
Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., & Felip, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt178 · Cited by 613
Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., Keijser, A., Faivre-Finn, C., & Senan, S. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61085-0 · Cited by 604
Faivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., Bezjak, A., Cardenal, F., Fournel, P., Harden, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30318-2 · Cited by 592
Rossi, A., Di Maio, M., Chiodini, P., Rudd, R. M., Okamoto, H., Skarlos, D. V., Früh, M., Qian, W., Tamura, T., Samantas, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4905 · Cited by 570
Lu, T., Yang, X., Huang, Y., Zhao, M., Li, M., Ma, K., Yin, J., Zhan, C., & Wang, Q. (2019) · Cancer Management and Research · doi:10.2147/cmar.s187317 · Cited by 561
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557
Morgensztern, D., Ng, S. H., Gao, F., & Govindan, R. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c5920c · Cited by 547
Self-citationLara, P. N., Natale, R., Crowley, J., Lenz, H. J., Redman, M. W., Carleton, J. E., Jett, J., Langer, C. J., Kuebler, J. P., Dakhil, S. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1061 · Cited by 525
Pesch, B., Kendzia, B., Gustavsson, P., Jöckel, K., Johnen, G., Pohlabeln, H., Olsson, A., Ahrens, W., Gross, I. M., Brüske, I., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27339 · Cited by 509
Sher, T., Dy, G. K., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.355 · Cited by 498
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, A. K. P., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., D'Amico, T. A., D'Avella, C., Dowlati, A., Downey, R. J., Edelman, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0058 · Cited by 486
Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Bianchi, F., Bettini, A., Longo, F., Moscetti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70310-3 · Cited by 475
Lung cancer: New biological insights and recent therapeutic advances
Ramalingam, S. S., Owonikoko, T. K., & Khuri, F. R. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20102 · Cited by 471
Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0011 · Cited by 436
Self-citationChung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H., Delord, J.-P., Gao, B., Planchard, D., Gottfried, M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.109 · Cited by 408
Eckardt, J. R., von Pawel, J., Pujol, J.-L., Papai, Z., Quoix, E., Ardizzoni, A., Poulin, R., Preston, A. J., Dane, G., & Ross, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3998 · Cited by 393
Zhou, J., Xu, Y., Liu, J., Feng, L., Yu, J., & Chen, D. (2024) · Cancer Epidemiology · doi:10.1016/j.canep.2024.102693 · Cited by 389
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2270 · Cited by 378
Lung Cancer Staging and Prognosis
Woodard, G. A., Jones, K. D., & Jablons, D. M. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-40389-2_3 · Cited by 366
Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010
Meza, R., Meernik, C., Jeon, J., & Cote, M. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121323 · Cited by 363
Rudin, C. M., Ismaila, N., Hann, C. L., Malhotra, N., Movsas, B., Norris, K., Pietanza, M. C., Ramalingam, S. S., Turrisi, A. T., & Giaccone, G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7918 · Cited by 350
Ramalingam, S. S., Dahlberg, S. E., Langer, C. J., Gray, R., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1144 · Cited by 348
Advances in neuroendocrine lung tumors
Travis, W. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq380 · Cited by 327
Morgensztern, D., Besse, B., Greillier, L., Santana-Davila, R., Ready, N., Hann, C. L., Glisson, B. S., Farago, A. F., Dowlati, A., Rudin, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1133 · Cited by 326
Self-citationAntibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304
“The development strategy for rovalpituzumab tesirine, on the other hand, is to seek an initial accelerated approval based on response rate in a single arm monotherapy trial in third-line or later treatment for SCLC, a setting for which there are no good treatment options available [91].”
BackgroundNCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018
Kalemkerian, G. P., Loo, B. W., Akerley, W., Attia, A., Bassetti, M., Boumber, Y., Decker, R., Dobelbower, M. C., Dowlati, A., Downey, R. J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0079 · Cited by 288
Self-citationCurrent Diagnosis and Management of Small-Cell Lung Cancer
Wang, S., Zimmermann, S., Parikh, K., Mansfield, A. S., & Adjei, A. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.034 · Cited by 282
Bai, H., Mao, L., Wang, H. S., Zhao, J., Yang, L., An, T. T., Wang, X., Duan, C. J., Wu, N. M., Guo, Z. Q., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3930 · Cited by 273
O’Keefe, E. B., Meltzer, J. P., & Bethea, T. N. (2015) · Frontiers in Public Health · doi:10.3389/fpubh.2015.00051 · Cited by 259
Giffin, M. J., Cooke, K., Lobenhofer, E. K., Estrada, J., Zhan, J., Deegen, P., Thomas, M., Murawsky, C. M., Werner, J., Liu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2845 · Cited by 258
Slotman, B. J., Mauer, M. E., Bottomley, A., Faivre-Finn, C., Kramer, G. W. P. M., Rankin, E. M., Snee, M., Hatton, M., Postmus, P. E., Collette, L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0746 · Cited by 254
Luo, J., Shen, L., & Zheng, D. (2014) · Scientific Reports · doi:10.1038/srep06269 · Cited by 212
Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.002 · Cited by 135
Holland, A. E., Wadell, K., & Spruit, M. A. (2013) · European Respiratory Review · doi:10.1183/09059180.00005613 · Cited by 115
Pan, B., Chen, Y., Song, H., Xu, Y., Wang, R., & Chen, L. (2015) · Oncotarget · doi:10.18632/oncotarget.2787 · Cited by 103
“Patients with resistant disease suffer early relapse; overall survival at 5 years is less than 5% [4].”
BackgroundLi, M., Zhang, Q., Fu, P., Li, P., Peng, A., Zhang, G., Song, X., Tan, M., Li, X., Liu, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037229 · Cited by 67
“The 5-year survival of patients with metastatic NSCLC is less than 10% [2,3].”
BackgroundWang, Y., Hu, G.-F., & Wang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136259 · Cited by 21
“Non-small-cell lung cancer (NSCLC) comprises ~85% of all lung cancer patients.(2) Among patients with NSCLC, ~70% present with locally advanced nonresectable disease (stage IIIB)(3) correspondence: Zhe-hai Wang Shandong Cancer Hospital Affiliated to shandong University, 440 Jiyan road, huaiyin, Jinan, shandong 250117,…”
Metadata
- Authors
- Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-10-01
- Volume
- 24
- Issue
- 28
- Pages
- 4539-4544
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131664752
- Cited by
- 1,845
- References
- 22
- FWCI
- 23.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.